Notably, the cohort of recurrent platinum-resistant ovarian cancer in TOPACIO indicated that the ORR among patients with or without BRCA1/2 mutations or homologous recombination deficiency (HRD) seemed to be similar (BRAC1/2-mutation: 18%, BRCA1/2-wt: 19%; HRD positive: 14%, HRD negative: 19%) [85]. The gene discussed is BRCA1; the disease is ovarian carcinoma.